Actively Recruiting
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Led by Columbia University · Updated on 2025-09-25
150
Participants Needed
2
Research Sites
174 weeks
Total Duration
On this page
Sponsors
C
Columbia University
Lead Sponsor
C
Cornell University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
CONDITIONS
Official Title
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years who have received a heart transplant and have not started CMV prophylaxis
You will not qualify if you...
- History of or suspected CMV disease within 6 months prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
NYP-Weill Cornell
New York, New York, United States, 10021
Actively Recruiting
2
Columbia University/NYP Milstein Hospital
New York, New York, United States, 10032
Actively Recruiting
Research Team
A
Afsana Rahman, MD
CONTACT
A
Adel T Alnatour, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here